Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia

Maliha Khan, Tariq Muzzafar, Hagop Kantarjian, Ifra Badar, Nicholas Short, Xuemei Wang, Kamal Chamoun, Preetesh Jain, Courtney DiNardo, Naveen Pemmaraju, Prithviraj Bose, Gautam Borthakur, Jorge Cortes, Srdan Verstovsek, Guillermo Garcia-Manero, Zeev Estrov

Research output: Contribution to journalArticle

Abstract

The impact of bone marrow fibrosis grade on the prognosis of patients with chronic myelomonocytic leukemia (CMML) remains controversial. Therefore, we examined the records of 82 patients diagnosed with CMML at our institution and summarized baseline characteristics and molecular profiles by subgroups of absent or mild (grades 0/1) and moderate (grade 2) fibrosis. Cox proportional hazards models were constructed to assess the prognostic significance of fibrosis grade. Grade 2 fibrosis was identified in 63 patients (76.8%), grade 1 in 16 patients (19.5%), and grade 0 in 3 patients (3.7%). Grade 2 fibrosis was associated with reduced hemoglobin levels (median 9.75 vs 11.0 g/dL in grade 0/1; p = 0.04) and increased percentages of ringed sideroblasts (7.5 vs 0%; p = 0.008). In multivariable analysis, grade 2 fibrosis was an independent predictor of poor overall survival (OS; 95% CI 1.32–6.35; HR 2.90; p = 0.008), but not event-free survival (EFS; 95% CI 0.62–2.67; HR 1.28; p = 0.50). Absolute neutrophil count (ANC) was found to impact OS (95% CI 1.01–1.09; HR 1.05; p = 0.009), while both ANC (95% CI 1.00–1.07; HR 1.04; p = 0.04) and peripheral blood blast percentage (95% CI 1.02–1.32; HR 1.16; p = 0.02) impacted EFS. These results implicate fibrosis grade is an important indicator of prognosis, with high-grade fibrosis predicting inferior survival. Given the prevalence of marrow fibrosis in CMML, fibrosis grading should be incorporated into prognostic assessment and therapeutic decision-making.

Original languageEnglish (US)
Pages (from-to)1183-1191
Number of pages9
JournalAnnals of Hematology
Volume97
Issue number7
DOIs
StatePublished - Jul 1 2018
Externally publishedYes

Fingerprint

Leukemia, Myelomonocytic, Chronic
Primary Myelofibrosis
Fibrosis
Survival
Neutrophils
Proportional Hazards Models
Disease-Free Survival
Decision Making
Hemoglobins
Bone Marrow

Keywords

  • Bone marrow fibrosis
  • CMML
  • Fibrosis grade
  • Prognosis

ASJC Scopus subject areas

  • Hematology

Cite this

Khan, M., Muzzafar, T., Kantarjian, H., Badar, I., Short, N., Wang, X., ... Estrov, Z. (2018). Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Annals of Hematology, 97(7), 1183-1191. https://doi.org/10.1007/s00277-018-3289-6

Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. / Khan, Maliha; Muzzafar, Tariq; Kantarjian, Hagop; Badar, Ifra; Short, Nicholas; Wang, Xuemei; Chamoun, Kamal; Jain, Preetesh; DiNardo, Courtney; Pemmaraju, Naveen; Bose, Prithviraj; Borthakur, Gautam; Cortes, Jorge; Verstovsek, Srdan; Garcia-Manero, Guillermo; Estrov, Zeev.

In: Annals of Hematology, Vol. 97, No. 7, 01.07.2018, p. 1183-1191.

Research output: Contribution to journalArticle

Khan, M, Muzzafar, T, Kantarjian, H, Badar, I, Short, N, Wang, X, Chamoun, K, Jain, P, DiNardo, C, Pemmaraju, N, Bose, P, Borthakur, G, Cortes, J, Verstovsek, S, Garcia-Manero, G & Estrov, Z 2018, 'Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia', Annals of Hematology, vol. 97, no. 7, pp. 1183-1191. https://doi.org/10.1007/s00277-018-3289-6
Khan, Maliha ; Muzzafar, Tariq ; Kantarjian, Hagop ; Badar, Ifra ; Short, Nicholas ; Wang, Xuemei ; Chamoun, Kamal ; Jain, Preetesh ; DiNardo, Courtney ; Pemmaraju, Naveen ; Bose, Prithviraj ; Borthakur, Gautam ; Cortes, Jorge ; Verstovsek, Srdan ; Garcia-Manero, Guillermo ; Estrov, Zeev. / Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. In: Annals of Hematology. 2018 ; Vol. 97, No. 7. pp. 1183-1191.
@article{8d58e58b83f74dbeaecbfc1b6e9059ec,
title = "Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia",
abstract = "The impact of bone marrow fibrosis grade on the prognosis of patients with chronic myelomonocytic leukemia (CMML) remains controversial. Therefore, we examined the records of 82 patients diagnosed with CMML at our institution and summarized baseline characteristics and molecular profiles by subgroups of absent or mild (grades 0/1) and moderate (grade 2) fibrosis. Cox proportional hazards models were constructed to assess the prognostic significance of fibrosis grade. Grade 2 fibrosis was identified in 63 patients (76.8{\%}), grade 1 in 16 patients (19.5{\%}), and grade 0 in 3 patients (3.7{\%}). Grade 2 fibrosis was associated with reduced hemoglobin levels (median 9.75 vs 11.0 g/dL in grade 0/1; p = 0.04) and increased percentages of ringed sideroblasts (7.5 vs 0{\%}; p = 0.008). In multivariable analysis, grade 2 fibrosis was an independent predictor of poor overall survival (OS; 95{\%} CI 1.32–6.35; HR 2.90; p = 0.008), but not event-free survival (EFS; 95{\%} CI 0.62–2.67; HR 1.28; p = 0.50). Absolute neutrophil count (ANC) was found to impact OS (95{\%} CI 1.01–1.09; HR 1.05; p = 0.009), while both ANC (95{\%} CI 1.00–1.07; HR 1.04; p = 0.04) and peripheral blood blast percentage (95{\%} CI 1.02–1.32; HR 1.16; p = 0.02) impacted EFS. These results implicate fibrosis grade is an important indicator of prognosis, with high-grade fibrosis predicting inferior survival. Given the prevalence of marrow fibrosis in CMML, fibrosis grading should be incorporated into prognostic assessment and therapeutic decision-making.",
keywords = "Bone marrow fibrosis, CMML, Fibrosis grade, Prognosis",
author = "Maliha Khan and Tariq Muzzafar and Hagop Kantarjian and Ifra Badar and Nicholas Short and Xuemei Wang and Kamal Chamoun and Preetesh Jain and Courtney DiNardo and Naveen Pemmaraju and Prithviraj Bose and Gautam Borthakur and Jorge Cortes and Srdan Verstovsek and Guillermo Garcia-Manero and Zeev Estrov",
year = "2018",
month = "7",
day = "1",
doi = "10.1007/s00277-018-3289-6",
language = "English (US)",
volume = "97",
pages = "1183--1191",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia

AU - Khan, Maliha

AU - Muzzafar, Tariq

AU - Kantarjian, Hagop

AU - Badar, Ifra

AU - Short, Nicholas

AU - Wang, Xuemei

AU - Chamoun, Kamal

AU - Jain, Preetesh

AU - DiNardo, Courtney

AU - Pemmaraju, Naveen

AU - Bose, Prithviraj

AU - Borthakur, Gautam

AU - Cortes, Jorge

AU - Verstovsek, Srdan

AU - Garcia-Manero, Guillermo

AU - Estrov, Zeev

PY - 2018/7/1

Y1 - 2018/7/1

N2 - The impact of bone marrow fibrosis grade on the prognosis of patients with chronic myelomonocytic leukemia (CMML) remains controversial. Therefore, we examined the records of 82 patients diagnosed with CMML at our institution and summarized baseline characteristics and molecular profiles by subgroups of absent or mild (grades 0/1) and moderate (grade 2) fibrosis. Cox proportional hazards models were constructed to assess the prognostic significance of fibrosis grade. Grade 2 fibrosis was identified in 63 patients (76.8%), grade 1 in 16 patients (19.5%), and grade 0 in 3 patients (3.7%). Grade 2 fibrosis was associated with reduced hemoglobin levels (median 9.75 vs 11.0 g/dL in grade 0/1; p = 0.04) and increased percentages of ringed sideroblasts (7.5 vs 0%; p = 0.008). In multivariable analysis, grade 2 fibrosis was an independent predictor of poor overall survival (OS; 95% CI 1.32–6.35; HR 2.90; p = 0.008), but not event-free survival (EFS; 95% CI 0.62–2.67; HR 1.28; p = 0.50). Absolute neutrophil count (ANC) was found to impact OS (95% CI 1.01–1.09; HR 1.05; p = 0.009), while both ANC (95% CI 1.00–1.07; HR 1.04; p = 0.04) and peripheral blood blast percentage (95% CI 1.02–1.32; HR 1.16; p = 0.02) impacted EFS. These results implicate fibrosis grade is an important indicator of prognosis, with high-grade fibrosis predicting inferior survival. Given the prevalence of marrow fibrosis in CMML, fibrosis grading should be incorporated into prognostic assessment and therapeutic decision-making.

AB - The impact of bone marrow fibrosis grade on the prognosis of patients with chronic myelomonocytic leukemia (CMML) remains controversial. Therefore, we examined the records of 82 patients diagnosed with CMML at our institution and summarized baseline characteristics and molecular profiles by subgroups of absent or mild (grades 0/1) and moderate (grade 2) fibrosis. Cox proportional hazards models were constructed to assess the prognostic significance of fibrosis grade. Grade 2 fibrosis was identified in 63 patients (76.8%), grade 1 in 16 patients (19.5%), and grade 0 in 3 patients (3.7%). Grade 2 fibrosis was associated with reduced hemoglobin levels (median 9.75 vs 11.0 g/dL in grade 0/1; p = 0.04) and increased percentages of ringed sideroblasts (7.5 vs 0%; p = 0.008). In multivariable analysis, grade 2 fibrosis was an independent predictor of poor overall survival (OS; 95% CI 1.32–6.35; HR 2.90; p = 0.008), but not event-free survival (EFS; 95% CI 0.62–2.67; HR 1.28; p = 0.50). Absolute neutrophil count (ANC) was found to impact OS (95% CI 1.01–1.09; HR 1.05; p = 0.009), while both ANC (95% CI 1.00–1.07; HR 1.04; p = 0.04) and peripheral blood blast percentage (95% CI 1.02–1.32; HR 1.16; p = 0.02) impacted EFS. These results implicate fibrosis grade is an important indicator of prognosis, with high-grade fibrosis predicting inferior survival. Given the prevalence of marrow fibrosis in CMML, fibrosis grading should be incorporated into prognostic assessment and therapeutic decision-making.

KW - Bone marrow fibrosis

KW - CMML

KW - Fibrosis grade

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=85046036977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046036977&partnerID=8YFLogxK

U2 - 10.1007/s00277-018-3289-6

DO - 10.1007/s00277-018-3289-6

M3 - Article

C2 - 29557496

AN - SCOPUS:85046036977

VL - 97

SP - 1183

EP - 1191

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 7

ER -